References
- Brons M, Muller SA, Rutten FH, et al. Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience. Eur Heart J Open. 2022;2(2):oeac011. doi: 10.1093/ehjopen/oeac011.
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2021;42(16):1554–1568. doi: 10.1093/eurheartj/ehab072.
- Sammani A, Jansen M, de Vries NM, et al. Automatic identification of patients with unexplained left ventricular hypertrophy in electronic health record data to improve targeted treatment and family screening. Front Cardiovasc Med. 2022;9:768847. doi: 10.3389/fcvm.2022.768847.
- Devesa A, Camblor Blasco A, Pello Lázaro AM, et al. Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. ESC Heart Fail. 2021;8(4):2856–2865. doi: 10.1002/ehf2.13360.
- Arana-Achaga X, Goena-Vives C, Villanueva-Benito I, et al. Development and validation of a prediction model and score for transthyretin cardiac amyloidosis diagnosis: t -Amylo. JACC Cardiovasc Imaging. 2023;16(12):1567–1580. doi: 10.1016/j.jcmg.2023.05.002.
- Davies DR, Redfield MM, Scott CG, et al. A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiol. 2022;7(10):1036–1044. doi: 10.1001/jamacardio.2022.1781.
- Boldrini M, Cappelli F, Chacko L, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(4):909–920. doi: 10.1016/j.jcmg.2019.10.011.
- Aimo A, Tomasoni D, Porcari A, et al. Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis. Eur J Heart Fail. 2023;25(4):510–514. doi: 10.1002/ejhf.2824.